Y-mAbs Therapeutics (YMAB) said Friday it is realigning its internal operations and establishing radiopharmaceuticals and Danyelza units.
The company expects a reduction in its current staffing of up to about 13%, and plans to transfer some jobs to the US from Denmark to better coordinate the advancement of its radiopharmaceutical platform and to make a small adjustment in the Danyelza commercial team.
Y-mAbs also reported preliminary full-year 2024 total net revenue of about $88 million, compared with its previously provided range of $87 million to $95 million. Analysts polled by FactSet expect $88.2 million.
Shares of the company were down by nearly 6% in recent Friday trading.
Price: 7.01, Change: -0.38, Percent Change: -5.14
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.